Telmisartan in daily clinical practice: factors affecting efficacy in treatment of primary arterial hypertension.

Simple item page
dc.contributor.authorBergovac, Men_US
dc.contributor.authorKnezević, Aen_US
dc.contributor.authorPlavec, Den_US
dc.contributor.authorTrkulja, Ven_US
dc.date.accessioned2009-01-27en_US
dc.date.accessioned2009-06-02T12:34:00Z
dc.date.available2009-01-27en_US
dc.date.available2009-06-02T12:34:00Z
dc.date.issued2009-01-27en_US
dc.description.abstractBACKGROUND: Telmisartan provides effective treatment of hypertension in a broad spectrum of patients. Aims: To evaluate factors affecting the efficacy of telmisartan in daily clinical practice. SETTING AND DESIGN: Prospective practice-based 12-week uncontrolled cohort study. MATERIALS AND METHODS: Consecutive incident/prevalent outpatients with mild to moderate essential hypertension were started on telmisartan 40 mg/day with optional up-titration to 80 mg/day in order to achieve seated systolic (SSBP) and diastolic (SDBP) blood pressure < 140/90 mm Hg. Intent-to-treat (ITT, N=282) and per protocol (PP, N=275) efficacy assessment was based on SSBP/SDBP reduction and delivered doses. RESULTS: SSBP/SDBP decreased (165.2+/-13.1 / 98.3+/-6.7 mm Hg to 137.9+/-13.2 / 82.6+/-7.3 mm Hg), whilst telmisartan was up-titrated in 40.5% of patients during the study. Multivariate (practically identical ITT and PP) analysis indicated poorer response in obese vs. non-obese patients: lesser SDBP reduction (by around 2.2-2.3 mm Hg, P < 0.05) with higher odds of dose up-titration (odds ratio, OR around 1.90, P < 0.05); and better response in: a) patients started on telmisartan monotherapy than when added to a preexisting treatment: greater SSBP/SDBP reduction (by around 4.0 and 3.0 mm Hg, respectively, P < 0.05) with comparable odds of up-titration; b) diabetics vs. non-diabetics: greater SDBP reduction (by around 3.6-3.7 mm Hg, P < 0.05) with comparable odds of up-titration; c) men vs. women: slightly greater SDBP reduction (by around 1.2 mm Hg, 0.05 P < 0.1) with lower odds of up-titration (OR around 0.51, P < 0.05). CONCLUSION: Previous unsuccessful treatment, obesity, diabetes and gender should be considered in order to optimize the use of telmisartan for mild to moderate essential hypertension in daily clinical practice.en_US
dc.description.affiliationDepartment of Pharmacology, Zagreb University School of Medicine, Zagreb, Croatia.en_US
dc.identifier.citationBergovac M, Knezević A, Plavec D, Trkulja V. Telmisartan in daily clinical practice: factors affecting efficacy in treatment of primary arterial hypertension. Journal of Postgraduate Medicine. 2009 Jan-Mar; 55(1): 27-32en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/116998
dc.language.isoengen_US
dc.source.urihttps://www.jpgmonline.comen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshAngiotensin II Type 1 Receptor Blockers --pharmacologyen_US
dc.subject.meshAntihypertensive Agents --pharmacologyen_US
dc.subject.meshArteries --physiopathologyen_US
dc.subject.meshBenzimidazoles --pharmacologyen_US
dc.subject.meshBenzoates --pharmacologyen_US
dc.subject.meshBlood Pressure --drug effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHypertension --drug therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMultivariate Analysisen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleTelmisartan in daily clinical practice: factors affecting efficacy in treatment of primary arterial hypertension.en_US
dc.typeJournal Articleen_US
dc.typeMulticenter Studyen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Postgraduate Medicine